All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
The CAR T-cell product axicabtagene ciloleucel (axi-cel) has become established as a successful treatment for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The efficacy and safety of axi-cel as a frontline treatment for high-risk LBCL is being investigated in the ZUMA-12 phase II clinical trial (NCT03761056). Interim study results have been previously reported by The Lymphoma Hub. Here, we summarize results from the primary analysis, published by Neelapu, et al., in Nature Medicine.1
The study is a multicenter, open-label, single-arm, phase II trial in adult patients with high-grade confirmed LBCL. High grade was defined as the presence of MYC and BCL2 and/or BCL6 translocations, or an International Prognostic Index ≥3 at any time prior to enrolment. Further information on the study design can be found here.
Table 1. Key patient baseline characteristics in ZUMA-12*
Baseline characteristic, n (%) |
N = 40 |
---|---|
Median age (range), years |
61 (23–86) |
≥65 years |
15 (38) |
Male |
27 (68) |
Disease stage III–IV |
38 (95) |
ECOG Performance Status ≥1 |
25 (63) |
One prior systemic line |
32 (100) |
Double- or triple-hit only |
6 (15) |
Double- or triple-hit and IPI ≥3 |
4 (10) |
IPI ≥3 only |
20 (50) |
Deauville score |
|
4 |
19 (48) |
5 |
21 (53) |
Alterations by FISH |
|
MYC |
19 (48) |
BCL2 |
15 (38) |
BCL6 |
10 (25) |
Previous systemic therapy |
|
R-CHOP |
19 (48) |
DA-EPOCH-R |
18 (45) |
Neither R-CHOP nor DA-EPOCH-R |
6 (15) |
DA-EPOCH-R, etoposide phosphate, prednisone, vincristine sulphate (Oncovin), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), and rituximab; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; IPI, International Prognostic Index; R-CHOP, rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone. |
Table 2. Most common Grade ≥3 adverse events in patients receiving axi-cel*
Adverse event, n (%) |
N = 40 |
---|---|
Neutropenia |
5 (13) |
Reduced neutrophil count |
21 (53) |
Reduced white cell count |
17 (43) |
Anemia |
12 (30) |
Encephalopathy |
6 (15) |
Thrombocytopenia |
6 (15) |
Hypoxia |
5 (12) |
*Data from Neelapu, et al.1 |
Considering biomarkers and CAR T-cell levels:
No statistical significance was found between median peak levels of CAR T-cells in patients who relapsed/did not respond, and those who had an ongoing response to axi-cel. Several cytokines were found to be at least doubled in patients who experienced Grade ≥3 neurological events, including interleukin (IL)-5, macrophage inflammatory protein-1α (MIP-1α), interferon (IFN)-γ, granulocyte-macrophage colony-stimulating factor (GM-CSF), ferritin, tumor necrosis factor (TNF)-α, IL-10, IL-8, and programmed death-ligand 1 (PDL1) (p < 0.05).
The primary analysis of the ZUMA-12 phase II trial suggests that axi-cel has potential as a safe and effective option for the frontline treatment for high-grade LBCL. In the cohort of 37 efficacy-evaluable patients, objective response rate and complete response rate were 89% and 78%, respectively, and CAR T-cell expansion was observed in all participants. Safety data is comparable to other studies using axi-cel, with manageable adverse events and toxicities. Larger, randomized control studies are needed to replicate these results in large study populations and further compare efficacy and safety data with current standard-of-care treatment.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox